ABBVIE INC.
AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
| (in millions, except per share data) | Quarter Ended June 30, 2024 | Full-Year Ended December 31, 2024 | ||||||||||
| Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | |||||||||
| Low | High | Low | High | |||||||||
| Previously announced guidance excluding Q2 2024 acquired IPR&D and milestones expense | $ | - | $ | 3.05 | $ | 3.09 | $ | 164 | $ | 11.13 | $ | 11.33 |
| Q2 2024 acquired IPR&D and milestones expense | 937 | (0.52) | (0.52) | 937 | (0.52) | (0.52) | ||||||
Guidance including Q2 2024 acquired IPR&D and milestones expensea
| $ | 937 | $ | 2.53 | $ | 2.57 | $ | 1,101 | $ | 10.61 | $ | 10.81 |
a The Company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2024, as both cannot be reliably forecasted.
1
Attachments
- Original Link
- Permalink
Disclaimer
AbbVie Inc. published this content on 03 July 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 July 2024 18:10:06 UTC.
